Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment target
The company said its Phase 3 TEBE-AM trial is nearing its 540-patient enrollment target, with topline data possible by the end of 2026.
Immunocore Holdings plc reported second quarter 2026 results on August 6, 2026, alongside a business update. Enrollment in the registrational Phase 3 TEBE-AM trial, which is testing tebentafusp alone and combined with pembrolizumab against a control arm in previously treated advanced cutaneous melanoma patients, is nearing its target of 540 patients, and the company said topline data from the event-driven trial could arrive as early as the end of 2026.1
The company also presented five-year survival data from KIMMTRAK's pivotal trial in metastatic uveal melanoma at the AACR 2026 meeting. KIMMTRAK doubled the likelihood of being alive at five years, with an overall survival rate of 16% versus 8% in the control arm (hazard ratio 0.67), and median overall survival of 21.6 versus 16.9 months.1
On the PRAME program, Phase 1/2 data presented at the 2026 ASCO meeting showed brenetafusp monotherapy produced a 17% overall response rate and 67% disease control rate at the 160 mcg dose versus 6% and 56% at 40 mcg, supporting the dose selected for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma.1
In infectious disease, the company completed enrollment of additional HIV patients at higher dose cohorts, up to 1200 mcg, in the multiple ascending dose part of its Phase 1/2 trial of IMC-M113V, with new data analysis planned to be shared early next year.1 In autoimmune disease, clinical trial sites for the Phase 1 trial of IMC-S118AI in type 1 diabetes are open, with the first patient expected to be dosed in the coming weeks.1 The company also plans to file a CTA or IND application in the second half of 2026 for a second autoimmune candidate, IMC-U120AI, targeting dermatological diseases including atopic dermatitis.1
On finances, net product revenue from KIMMTRAK was $115.9 million in the second quarter of 2026, up from $98.0 million a year earlier.1 Cash, cash equivalents and marketable securities stood at $880.2 million as of June 30, 2026, compared with $864.2 million at year-end 2025.1 The company expects to pay about $120 million in sales-related rebate accruals during the second half of 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.